Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| T47D | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 22.6 | uM | 7542.092 | 0.6240 | 0.4718 | 1.5380 | |
| T47D | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 113 | uM | 7542.092 | 0.0126 | -0.8837 | 1.5380 | |
| T47D | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 565 | uM | 7542.092 | 0.0081 | -0.9130 | 1.5380 | |
| T47D | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00145 | uM | 7543.091 | 0.9608 | 0.9466 | 1.4781 | |
| T47D | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00723 | uM | 7543.091 | 1.0172 | 1.0233 | 1.4781 | |
| T47D | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.0362 | uM | 7543.091 | 0.9624 | 0.9488 | 1.4781 | |
| T47D | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.181 | uM | 7543.091 | 0.9533 | 0.9363 | 1.4781 | |
| T47D | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.904 | uM | 7543.091 | 0.9941 | 0.9920 | 1.4781 | |
| T47D | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 4.52 | uM | 7543.091 | 0.9204 | 0.8908 | 1.4781 | |
| T47D | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 22.6 | uM | 7543.091 | 0.5151 | 0.2767 | 1.4781 | |
| T47D | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 113 | uM | 7543.091 | 0.0121 | -0.8990 | 1.4781 | |
| T47D | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 565 | uM | 7543.091 | 0.0034 | -0.9571 | 1.4781 | |
| T47DKBLUC | Unknown | Unknown | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00145 | uM | 7544.092 | 0.9577 | 0.9239 | 1.1147 | |
| T47DKBLUC | Unknown | Unknown | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00723 | uM | 7544.092 | 0.8911 | 0.8034 | 1.1147 | |
| T47DKBLUC | Unknown | Unknown | Imatinib | ABL/KIT/PDGFR | nRTK | 0.0362 | uM | 7544.092 | 0.9655 | 0.9380 | 1.1147 | |
| T47DKBLUC | Unknown | Unknown | Imatinib | ABL/KIT/PDGFR | nRTK | 0.181 | uM | 7544.092 | 1.0023 | 1.0041 | 1.1147 | |
| T47DKBLUC | Unknown | Unknown | Imatinib | ABL/KIT/PDGFR | nRTK | 0.904 | uM | 7544.092 | 1.0571 | 1.1021 | 1.1147 | |
| T47DKBLUC | Unknown | Unknown | Imatinib | ABL/KIT/PDGFR | nRTK | 4.52 | uM | 7544.092 | 0.9293 | 0.8726 | 1.1147 | |
| T47DKBLUC | Unknown | Unknown | Imatinib | ABL/KIT/PDGFR | nRTK | 22.6 | uM | 7544.092 | 0.7322 | 0.5122 | 1.1147 | |
| T47DKBLUC | Unknown | Unknown | Imatinib | ABL/KIT/PDGFR | nRTK | 113 | uM | 7544.092 | 0.0132 | -0.9587 | 1.1147 | |
| T47DKBLUC | Unknown | Unknown | Imatinib | ABL/KIT/PDGFR | nRTK | 565 | uM | 7544.092 | 0.0104 | -0.9669 | 1.1147 | |
| T47DKBLUC | Unknown | Unknown | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00145 | uM | 7545.092 | 0.9664 | 0.9315 | 0.9794 | |
| T47DKBLUC | Unknown | Unknown | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00723 | uM | 7545.092 | 0.9398 | 0.8771 | 0.9794 | |
| T47DKBLUC | Unknown | Unknown | Imatinib | ABL/KIT/PDGFR | nRTK | 0.0362 | uM | 7545.092 | 1.0180 | 1.0368 | 0.9794 | |
| T47DKBLUC | Unknown | Unknown | Imatinib | ABL/KIT/PDGFR | nRTK | 0.181 | uM | 7545.092 | 0.9993 | 0.9986 | 0.9794 |